Maravai LifeSciences
MRVI
158 hedge funds and large institutions have $344M invested in Maravai LifeSciences in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 52 reducing their positions, and 24 closing their positions.
19% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.08M
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
1% less funds holding
Funds holding: 159 → 158 (-1)
2% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 52
6.28% less ownership
Funds ownership: 89.23% → 82.95% (-6.3%)
18% less capital invested
Capital invested by funds: $421M → $344M (-$77.2M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$6.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.94M |
| 3 |
Two Sigma Investments
New York
|
+$2.49M |
| 4 |
First Eagle Investment Management
New York
|
+$2.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.89M |
Top Sellers
MRVI Hedge Fund Activity: Q1 2026 in Review
158 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2026, worth a combined $344M — down 18% from $421M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MRVI positions and 24 closed out — a net gain of 4 holders — while 51 added to existing stakes and 52 trimmed.
The largest buyer was Braidwell, adding an estimated $6.4M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $18.1M.
- 158 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2026, down from 159 in Q4 2025.
- Funds reported $344M of Maravai LifeSciences stock for Q1 2026, down 18% quarter-over-quarter.
- 28 funds opened new Maravai LifeSciences positions in Q1 2026 and 24 closed out, a net change of +4 holders.
- The largest Maravai LifeSciences buyer in Q1 2026 was Braidwell, an estimated $6.4M added.
- The largest Maravai LifeSciences seller in Q1 2026 was T. Rowe Price Investment Management, an estimated $18.1M sold.
Based on aggregated 13F filings for Q1 2026.